ExodusPoint Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

ExodusPoint Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-28,948	Closed	-$138K	–	2567
2022 Q1	$138K	Buy	+28,948	New	+$87.2K	﹤0.01%	1969
2021 Q2	–	Sell	-60,443	Closed	-$559K	–	2911
2021 Q1	$559K	Buy	+60,443	New	+$630K	0.01%	1268
2020 Q1	–	Sell	-423	Closed	-$5K	–	1745
2019 Q4	$5K	Buy	+423	New	+$7.08K	﹤0.01%	1480

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

ExodusPoint Capital Management's VIRX Position: Q2 2022 in Review

ExodusPoint Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2022, closing a stake of 28,948 shares — an estimated $138K sold.

ExodusPoint Capital Management first reported a position in VIRX in Q4 2019 and held it in 3 quarters. The position peaked at $559K in Q1 2021. 63 funds tracked by Wall St. Rank hold VIRX as of Q2 2022.

ExodusPoint Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 28,948 Viracta Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $138K.
ExodusPoint Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
ExodusPoint Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $559K in Q1 2021.
63 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.